Affect Therapeutics is a team of passionate people who are changing the way the world treats addiction.

Drug overdose deaths have reached record levels in the US, with no signs of abating. And yet, the standard of care for substance use disorders is largely based on decades-old approaches with generally poor patient outcomes. By thoughtfully innovating with sound research, data, and well-proven engagement techniques, we can change all of that.

We deliver treatments that are purpose-built for a variety of specific substance use disorders. We don’t use derivative approaches that don’t work, and we don’t subscribe to the “department store” model of addiction treatment, where one program is used to treat many different types of disorders. We believe each disease requires its own intervention, backed by science.

We are relentless in developing innovative, evidence-based solutions that we deliver with extraordinary care and empathy.

Spotlight On Our Care Team

Saleem Malik

Saleem Malik, CADC, is one of Affect’s certified counselors.

I have been in recovery from crystal meth addiction for over 10 years. I love music, martial arts, and cooking.  I am a single dad and I have been a counselor for almost 8 years.

“I believe as people we should be constantly striving to improve our mental, physical and spiritual health. To do this in the behavioral health field we need to find adaptive ways to deliver effective solutions to our members and this is why I value our approach at Affect Therapeutics. When you are green you grow and when you are ripe you rot.”

Dr. Ashley Jandes

Anastasia Ashley Jandes, MD, PharmD, IFMCP is Affect’s Medical Director.

“Affect Therapeutics was created to bring research and a best practice clinical model directly into the treatment of methamphetamine and cocaine use disorders. This is a living model and as it learns, grows, and develops, the body of knowledge and data is rolled out to patients immediately. This is a break from the traditional separation of research and clinical care with treatments often falling years behind the research data.

“We do not have the luxury of that kind of time. Methamphetamine related overdose deaths have nearly tripled over the past four years and cocaine overdose related deaths are also on the rise. Affect is in the forefront of creating this action in a model that blends state-of-the-art technology, research, and compassionate, evidence-based, and accessible clinical care delivered directly to the patient. I am proud to now be part of this team and hope to contribute to and grow this important body of work.”

Renee Mullings

Renee Mullings is a Clinical Supervisor for Affect Therapeutics

“I have worked in the field of addiction for over a decade.  I began this journey as a Substance Abuse Counselor. I moved on to become a Program Director, and then a Director of Operations. I am very excited to be working with the amazing staff here at Affect Therapeutics! Everyone from the CEO down is so genuine and caring!

“We all have one goal in mind… To help those struggling with addiction to regain their lives and thrive. There is absolutely no other type of work or industry that I would rather work in outside of the substance use population.  I have a passion to help those struggling with addiction, and to see them whole and happy.

“Recovery is possible! ‘We rise by lifting others up’ – Robert Ingersoll”

Executive Team

Jeff De Flavio, Executive Chairman

Jeff co-founded Affect Therapeutics and is an entrepreneur in residence at AlleyCorp. A physician by training, Jeff has dedicated his career to broadening access to healthcare and driving clinical innovation in addiction treatment. Dr. De Flavio was the founding CEO of Groups: Recover Together, which is now the largest value-based opiate addiction treatment provider in the United States. He is also a co-founder of Tempest, an online alcohol addiction treatment program.

Kristin Muhlner, CEO

As CEO, Kristin brings a depth of expertise in building digital technology companies across both the business and consumer landscapes, with a particular passion for driving the innovative use of data and analytics to solve real-world problems. Prior leadership roles include President of Framebridge, EVP of Sales for Sprinklr (NYSE:CXM), CEO of newBrandAnalytics (acquired by Sprinklr), and EVP of Engineering at webMethods (acquired by Software AG). She loves science fiction, crossword puzzles, and bulldogs, and she will happily play anyone anytime at Scrabble.

Rachel Lin

Rachel brings her passion for building innovative and engaging products in healthcare to Affect. She previously served as the first product manager at Cityblock, and was an early product manager at Uber. She is equally as passionate about J.R.R. Tolkien and can quote nearly all nine hours of the Lord of the Rings Trilogy. She co-founded the business with Jeff and Kristin and serves as its Head of Product.

Andrea Lapus

Andrea brings her dedication and experience in all things mathematical to the Finance and Accounting function at Affect Therapeutics. Her extensive career experience in the profession includes public accounting, early-stage technology, and eCommerce companies (AddThis,
Framebridge, Binary Fountain) and large Fortune 500 companies (Sony, MCI, AOL, Oracle). Andrea is the proud mother of two teenage boys, enjoys road trips and seeking out new adventures.

Russell Osborne

Russell brings his love of technology and great design to Affect in his role as the company’s Chief Technology Officer. He has dedicated the last fifteen years to building software for the healthcare, e-commerce, and manufacturing industries in order to help those around him. He is the father of two daughters, a car guy, and a complete and utter goofball.


Bryan Prout

Bryan has responsibility for the entire member journey, to include leading Affect’s clinical and operations teams. In doing so, he brings his significant experience building customer-centric organizations to the domain of addiction recovery. Bryan enjoys discovering new music, cheering on a variety of mostly bad sports franchises, chasing his 3 young children around the Blue Ridge Mountains, and deploying arcane movie references.

Will Herling

At Affect, Will combines his expertise in value-based care and his passion for addiction advocacy to build partnerships that will transform the recovery landscape. Prior to Affect, he led SUD alternative payment model efforts at Remedy Partners and pursued his MBA/MPH at UC Berkeley. Will also organizes The Showdown on the Sound, a “build your own boat” race, in honor of his friend who passed away from an overdose. He hasn’t won it yet, but this is his year. 

Advisors and Board Members

Haden Blackman

Haden is a highly celebrated writer and game designer, having authored the award winning series Batwoman and written well-known video games including Star Wars: The Force Unleashed and Mafia III. He brings his storytelling and design expertise to Affect and advises the company in the development of engaging products.

Thomas McLellan

Dr. McLellan is one of the most published researchers in the field of substance use disorder treatments. He served as Deputy Director of the Office of National Drug Control Policy and in 2003 was awarded the Life Achievement Award by the American Society of Addiction Medicine. He brings his depth of expertise to help guide Affect in the development of its treatment programs.

Larissa Mooney

Dr. Mooney is the Director of Addiction Psychiatry at UCLA and is a specialist in the treatment of and research regarding substance use disorders, including methamphetamine use disorder. She advises Affect on its clinical interventions and research initiatives.

Jeff Rinehart

Jeff is a partner at City Light, which invests in companies that drive social impact. Prior to joining City Light, Jeff was a senior marketing executive at a number of highly successful companies including Capital One and 2U. He serves on the board of directors for Affect.

Kevin P. Ryan

Kevin is an investor and entrepreneur and has founded several New York-based businesses, including Gilt Groupe, Business Insider, and MongoDB. Kevin continues to found and invest in companies, including Affect Therapeutics, through AlleyCorp, a venture firm he founded in 2008. Kevin serves on the board of directors for Affect.

Gaurav Singal

Dr. Singal is a healthcare executive, trained as both a physician and computer scientist, who works to transform healthcare through innovative technology. He previously served as Chief Data Officer of Foundation Medicine and advises Affect on its data science and analytics initiatives.

Are you ready to get started? We can’t wait to meet you!

As Seen On

Affect's innovative approach to treating the meth and crack crisis and beating addiction has been recognized by Forbes magazine
Tech Crunch covered how Affect is treating meth and cocaine addiction with an innovative digital recovery program backed by science and data
Cheddar News covered Affect's use of gamification and game design theory to activate the brain's reward center and get meth and cocaine addicts hooked on their recovery